cardiology approach does not create adverse effects and may be supportive for patients with DD.
Metabolic cardiology may be another treatment option to support DD, along with use of targeted nutraceutical therapies including CoQ10, D-ribose, L-carnitine, and magnesium to help fortify insufficient ATP levels in heart tissue. Although inflammatory cardiomyopathy may be a cause of DD, inflammatory CAD is a more common manifestation of inflammation in the heart. Clinically, we find the five biomarkers listed previously useful for helping clinicians assess cardiovascular risk in healthy and diseased populations. In addition, in comparison to standard lipid panels, these biomarkers can also provide additional information to guide clinicians with targeted treatments to reduce the inflammatory burden in the body as well as the heart.
Ideally, levels should be between 180 and 350 mg/dL. One of the best lifestyle interventions for lowering fibrinogen is to stop smoking. Weight loss and exercise seem to have only a modest effect. Omega-3s and nattokinase may lower fibrinogen as well.